DPP-4 Inhibitors and GLP‑1 Analogues

Introduction / Overview

Diabetes mellitus type 2 (T2DM) remains a global public health challenge, with an escalating prevalence driven by ageing populations, sedentary lifestyles, and increasing rates of obesity. Recent therapeutic advances have focused on agents that enhance endogenous incretin activity, thereby improving glycaemic control while addressing post‑prandial hyperglycaemia and weight management. Incretin‑based therapies, comprising dipeptidyl peptidase‑4 (DPP‑4) inhibitors and glucagon‑like peptide‑1 (GLP‑1) receptor agonists, have emerged as cornerstone treatments in contemporary diabetes management guidelines. Their distinct mechanisms of action, pharmacokinetic profiles, and clinical benefits and risks underpin their selection in individualized treatment regimens.

Clinical relevance is underscored by the dual benefits of glycaemic control and cardiovascular risk reduction observed in large outcome trials, especially with certain GLP‑1 analogues. Moreover, the oral administration of DPP‑4 inhibitors offers a convenient alternative to subcutaneous GLP‑1 analogues, expanding therapeutic options for patients with adherence challenges. As a result, an in‑depth understanding of these drug classes is essential for medical and pharmacy students preparing to manage patients with T2DM.

• Learning Objectives
• Identify the pharmacological classification and chemical structures of DPP‑4 inhibitors and GLP‑1 analogues.
• Describe the mechanisms of action, including receptor interactions and downstream cellular signalling pathways.
• Summarize the pharmacokinetic parameters influencing dosing and therapeutic monitoring.
• Recognise approved indications, off‑label uses, and patient populations most likely to benefit.
• Analyse adverse effect profiles, drug interactions, and special considerations in vulnerable populations.

Classification

DPP‑4 Inhibitors

DPP‑4 inhibitors, also known as gliptins, are small‑molecule, orally administered agents that selectively inhibit the DPP‑4 enzyme. They are chemically diverse, comprising pyridazinone, pyrimidinone, and thiazolidinone backbones. The most widely utilized agents include sitagliptin, saxagliptin, linagliptin, alogliptin, and vildagliptin. All share a common pharmacodynamic target—DPP‑4—but differ in their pharmacokinetic attributes and dosing schedules.

GLP‑1 Receptor Agonists

GLP‑1 analogues are peptide‑based, mimicking the endogenous incretin hormone GLP‑1 (7–36) amide. They are structurally modified to resist enzymatic degradation and prolong receptor engagement. Representative agents include exenatide, liraglutide, dulaglutide, semaglutide, and albiglutide. These drugs are administered subcutaneously, with dosing frequencies ranging from twice daily to weekly injections, depending on the formulation.

Mechanism of Action

DPP‑4 Inhibitors

DPP‑4 is a serine protease expressed on the surface of various cell types, responsible for rapid cleavage of incretin hormones GLP‑1 and glucose‑dependent insulinotropic polypeptide (GIP). Inhibition of DPP‑4 prolongs the half‑life of circulating GLP‑1 and GIP, thereby enhancing their insulinotropic and glucagonostatic effects. The primary pharmacodynamic actions include:

• Enhanced post‑prandial insulin secretion from pancreatic β‑cells, mediated by increased intracellular cyclic adenosine monophosphate (cAMP) and subsequent calcium influx.
• Suppressed glucagon release from α‑cells during hyperglycaemia, reducing hepatic gluconeogenesis and glycogenolysis.
• Modest reduction in gastric emptying, contributing to lower post‑prandial glucose excursions.

Unlike GLP‑1 analogues, DPP‑4 inhibitors do not activate the GLP‑1 receptor directly; rather, they potentiate endogenous ligand availability. This indirect mechanism yields a physiological insulinotropic response, which is glucose‑dependent and thus carries a lower risk of hypoglycaemia when used as monotherapy.

GLP‑1 Receptor Agonists

GLP‑1 analogues bind with high affinity to the GLP‑1 receptor (GLP‑1R) on pancreatic β‑cells and other target tissues. Binding initiates heterotrimeric G‑protein signalling, predominantly via the Gαs subunit, leading to adenylate cyclase activation and increased cAMP production. Elevated cAMP activates protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC), which synergistically promote insulin gene transcription, β‑cell proliferation, and survival. In α‑cells, GLP‑1R activation inhibits cyclic AMP‑dependent glucagon secretion. Additionally, GLP‑1 receptor activation in the central nervous system and gastrointestinal tract modulates satiety, gastric emptying, and energy expenditure, thereby contributing to weight loss. The pharmacodynamic profile of GLP‑1 analogues is characterised by sustained receptor occupancy, which underpins their once‑daily or weekly dosing regimens.

Pharmacokinetics

DPP‑4 Inhibitors

Absorption and bioavailability vary among agents. Sitagliptin demonstrates a 60–80 % oral bioavailability with peak plasma concentrations reached within 2–4 h post‑dose. Saxagliptin undergoes hepatic oxidation to an active metabolite; both parent and metabolite contribute to pharmacologic activity. Linagliptin shows a high oral bioavailability (~80 %) and minimal hepatic metabolism, primarily excreted unchanged via the bile. Alogliptin and vildagliptin are also well absorbed, with peak concentrations achieved within 1–2 h. Bioavailability is generally unaffected by food; however, certain agents (e.g., linagliptin) exhibit a dose‑dependent absorption profile.

Distribution is widespread, with most agents exhibiting moderate plasma protein binding (< 30 %). The volume of distribution (Vd) for sitagliptin is approximately 0.2 L/kg, whereas linagliptin demonstrates a larger Vd (~0.4 L/kg) due to its lipophilic character. The central nervous system penetration is limited, reflecting a low blood‑brain barrier permeability.

Metabolism predominantly involves hepatic cytochrome P450 (CYP) enzymes for some agents (e.g., saxagliptin, alogliptin), whereas others rely on non‑CYP pathways. Excretion pathways differ: sitagliptin is cleared via renal tubular secretion and glomerular filtration; linagliptin is eliminated via biliary excretion with negligible renal involvement; saxagliptin and alogliptin are excreted in urine as metabolites. Consequently, dose adjustments are necessary in renal impairment, especially for sitagliptin, saxagliptin, and alogliptin. Hepatic impairment has a minimal impact on most gliptins, except for saxagliptin, which may require monitoring.

The elimination half‑life ranges from 8 to 12 h for sitagliptin and linagliptin, supporting once‑daily dosing. Saxagliptin and alogliptin have slightly longer half‑lives (~12 h), whereas vildagliptin’s half‑life is approximately 2 h, necessitating twice‑daily administration. Pharmacokinetic variability is generally low, facilitating predictable therapeutic outcomes.

GLP‑1 Receptor Agonists

GLP‑1 analogues are peptides that are not orally bioavailable due to enzymatic degradation in the gastrointestinal tract and poor permeability. Consequently, they are administered subcutaneously, with absorption dependent on local blood flow and formulation excipients. Exenatide (short‑acting) achieves detectable plasma concentrations within 30–60 min, while long‑acting formulations (liraglutide, dulaglutide, semaglutide, albiglutide) display a slower absorption profile owing to their pegylation or fusion to albumin, which extends half‑life.

Distribution is largely confined to extracellular fluid; protein binding varies: liraglutide is highly albumin‑bound (≈ 95 %), whereas exenatide demonstrates moderate binding (~ 30 %). Volume of distribution is modest, reflecting limited tissue penetration.

Metabolism occurs via proteolytic cleavage by endogenous peptidases, followed by hepatic and renal clearance. Exenatide is primarily cleared by the kidneys; thus, dose adjustments are required in patients with impaired renal function. Long‑acting analogues are metabolised slower, with semaglutide demonstrating a half‑life of 7–9 days, enabling weekly dosing. Liraglutide and dulaglutide have half‑lives of 13 h and 5–7 days, respectively, supporting once‑daily and once‑weekly regimens.

Renal impairment affects exenatide clearance most profoundly, whereas hepatic impairment has a comparatively modest impact on long‑acting analogues. Therefore, caution is advised when prescribing exenatide to patients with chronic kidney disease.

Therapeutic Uses / Clinical Applications

Approved Indications

DPP‑4 inhibitors are indicated as adjunctive therapy to diet and exercise for the management of adults with T2DM. They may be used alone or in combination with metformin, sulfonylureas, insulin, or other glucose‑lowering agents. GLP‑1 receptor agonists are approved for glycaemic control in adults with T2DM, either as monotherapy or in combination with other agents. Certain GLP‑1 analogues (e.g., semaglutide and dulaglutide) receive additional approvals for chronic weight management in obese or overweight individuals without diabetes, reflecting their robust anti‑obesity effects.

Off‑Label and Emerging Uses

• Combination with sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitors to achieve synergistic glycaemic and weight benefits.
• Use in patients with type 1 diabetes in combination with insulin to reduce post‑prandial glucose excursions, although regulatory approval is pending.
• Potential neuroprotective and cardiovascular benefits beyond glycaemic control, supported by emerging evidence of plaque stabilization and endothelial function improvement.

Patient Populations Benefiting Most

Patients with early‑stage T2DM, those requiring improvement in post‑prandial glucose, and individuals prioritising weight loss or cardiovascular risk reduction are prime candidates. DPP‑4 inhibitors are particularly suitable for patients with renal impairment due to their minimal hepatic metabolism. GLP‑1 analogues are preferred for patients with a high risk of cardiovascular events, given evidence of reduced major adverse cardiovascular events (MACE) with certain agents. Weight‑focused therapies are indicated in obese patients, especially when lifestyle interventions are insufficient.

Adverse Effects

DPP‑4 Inhibitors

Common side effects are generally mild and include nasopharyngitis, headache, upper respiratory tract infections, and arthralgia. Hypoglycaemia is rare when used as monotherapy but may occur when combined with insulin or sulfonylurea agents due to additive insulinotropic effects.

Serious adverse reactions encompass:

• Allergic reactions, such as rash, pruritus, or urticaria.
• Impaired renal function in patients with pre‑existing renal disease.
• Potential for pancreatitis, although causality remains uncertain; vigilance is advisable.
• Risk of heart failure exacerbation has been suggested in some studies; caution is warranted in patients with reduced ejection fraction.

There are no black box warnings for DPP‑4 inhibitors, but clinicians should monitor for signs of pancreatitis and renal dysfunction.

GLP‑1 Receptor Agonists

Adverse events are more frequent and include nausea, vomiting, and diarrhoea, particularly during dose escalation. These gastrointestinal symptoms are dose‑dependent and tend to diminish over time. Hypoglycaemia is uncommon unless combined with insulin or sulfonylureas.

Serious reactions include:

• Pancreatitis, with an incidence of < 0.1 % per year; patients should be advised to report persistent abdominal pain.
• Thyroid C‑cell tumors observed in rodent studies; no definitive evidence exists in humans, but monitoring is prudent.
• Injection site reactions (erythema, induration, pruritus) with subcutaneous administration.

A black box warning for pancreatitis is present for all GLP‑1 analogues. The risk of acute kidney injury has been reported in rare cases, possibly related to volume depletion from gastrointestinal side effects.

Drug Interactions

DPP‑4 Inhibitors

Drug–drug interactions are limited due to the lack of significant CYP involvement for most gliptins. However, the following interactions are noteworthy:

• Saxagliptin—CYP3A4 inhibitors/inducers may alter its metabolism; caution is advised with ketoconazole, clarithromycin, rifampin, and carbamazepine.
• Co‑administration with drugs that increase the risk of hypoglycaemia (e.g., insulin, sulfonylureas) necessitates monitoring of blood glucose levels.
• Potential additive renal toxicity when combined with other nephrotoxic agents such as non‑steroidal anti‑inflammatory drugs.

GLP‑1 Receptor Agonists

Interactions primarily stem from shared metabolic pathways or additive pharmacodynamic effects:

• Beta‑blockers may mask hypoglycaemic symptoms if GLP‑1 analogues are used in combination with insulin or sulfonylureas.
• Glucocorticoids can increase appetite and counteract weight‑loss benefits of GLP‑1 agonists.
• Co‑administration with drugs that prolong the QT interval is unlikely to be additive; however, caution is advised if the patient is on multiple QT‑prolonging agents.
• Exenatide and other GLP‑1 analogues may reduce the absorption of oral contraceptives due to delayed gastric emptying; patients should use barrier methods concurrently.

Special Considerations

Use in Pregnancy / Lactation

Both DPP‑4 inhibitors and GLP‑1 analogues lack sufficient human data regarding teratogenicity; animal studies have not indicated overt teratogenic effects, but the potential for adverse fetal development cannot be excluded. Consequently, these agents are generally contraindicated in pregnancy (Class C). Lactation considerations reveal minimal transfer into breast milk; however, the systemic exposure is negligible, and the benefit–risk ratio remains uncertain.

Pediatric Considerations

Off‑label use of DPP‑4 inhibitors in adolescents with T2DM has been reported, yet robust clinical trials are limited. GLP‑1 analogues are approved for use in children ≥10 years with T2DM (e.g., liraglutide). Dosing adjustments are required based on weight and renal function. Monitoring of growth parameters and potential gastrointestinal side effects is recommended.

Geriatric Considerations

Age‑related decline in renal function necessitates dose adjustments for DPP‑4 inhibitors such as sitagliptin and saxagliptin. GLP‑1 analogues are generally well tolerated in older adults, but careful monitoring for hypotension and volume depletion is advised. Polypharmacy increases the risk of drug interactions, particularly with agents affecting renal clearance.

Renal / Hepatic Impairment

Renal impairment influences the pharmacokinetics of most DPP‑4 inhibitors; dose reduction or avoidance is indicated when eGFR < 30 mL/min/1.73 m². Linagliptin is unique in that it requires no dose adjustment regardless of renal function, owing to its biliary excretion.

Hepatic impairment affects DPP‑4 inhibitors variably. Saxagliptin requires dose adjustment when hepatic enzymes are elevated. GLP‑1 analogues are primarily metabolised hepatically, but hepatic impairment has a minimal effect on overall pharmacokinetics; however, caution is warranted in severe hepatic disease (Child‑Pugh C). Exenatide must be avoided in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²). Long‑acting GLP‑1 analogues (semaglutide, dulaglutide) can be used with dose adjustment in moderate renal impairment but are contraindicated in severe disease.

Summary / Key Points

• DPP‑4 inhibitors prolong endogenous incretin activity, offering modest glucose lowering with a low hypoglycaemia risk.
• GLP‑1 analogues directly activate GLP‑1 receptors, producing significant glucose lowering, weight loss, and cardiovascular benefit.
• Renal function dictates dosing for most gliptins; linagliptin remains dose‑agnostic in renal impairment.
• Gastrointestinal adverse events are common with GLP‑1 analogues but tend to diminish with dose titration.
• Pancreatitis and thyroid C‑cell tumour signals necessitate caution; patients should be counselled on symptom recognition.
• Combination therapy with SGLT‑2 inhibitors and GLP‑1 analogues may enhance glycaemic control and cardiovascular protection.
• Pregnancy and lactation contraindicate both classes; pediatric use should be individualized and monitored.
• Clinicians should screen for renal and hepatic impairment before initiating therapy and adjust doses accordingly.

In summary, DPP‑4 inhibitors and GLP‑1 analogues represent pivotal advances in the pharmacologic management of T2DM, offering distinct mechanisms, pharmacokinetic properties, and clinical benefits. Mastery of their therapeutic profiles enables physicians and pharmacists to tailor treatment plans that optimise glycaemic control, mitigate cardiovascular risk, and improve patient adherence and quality of life.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.